JP2019520034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520034A5 JP2019520034A5 JP2018550322A JP2018550322A JP2019520034A5 JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5 JP 2018550322 A JP2018550322 A JP 2018550322A JP 2018550322 A JP2018550322 A JP 2018550322A JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- human
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 61
- 108091007433 antigens Proteins 0.000 claims 61
- 102000036639 antigens Human genes 0.000 claims 61
- 230000027455 binding Effects 0.000 claims 60
- 101150036449 SIRPA gene Proteins 0.000 claims 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 239000012634 fragment Substances 0.000 claims 27
- 230000003278 mimic effect Effects 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 102000044459 human CD47 Human genes 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000003053 immunization Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022112873A JP7549626B2 (ja) | 2016-04-14 | 2022-07-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322707P | 2016-04-14 | 2016-04-14 | |
| US62/322,707 | 2016-04-14 | ||
| EP17305182 | 2017-02-17 | ||
| EP17305182.2 | 2017-02-17 | ||
| PCT/EP2017/059071 WO2017178653A2 (en) | 2016-04-14 | 2017-04-14 | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112873A Division JP7549626B2 (ja) | 2016-04-14 | 2022-07-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520034A JP2019520034A (ja) | 2019-07-18 |
| JP2019520034A5 true JP2019520034A5 (enExample) | 2020-05-21 |
| JP7491666B2 JP7491666B2 (ja) | 2024-05-28 |
Family
ID=65529144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550322A Active JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
| JP2022112873A Active JP7549626B2 (ja) | 2016-04-14 | 2022-07-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112873A Active JP7549626B2 (ja) | 2016-04-14 | 2022-07-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11279766B2 (enExample) |
| EP (1) | EP4438626A3 (enExample) |
| JP (2) | JP7491666B2 (enExample) |
| KR (1) | KR102355240B1 (enExample) |
| CN (1) | CN115785272A (enExample) |
| CL (1) | CL2018002898A1 (enExample) |
| DK (1) | DK3443010T3 (enExample) |
| ES (1) | ES2990971T3 (enExample) |
| FI (1) | FI3443010T3 (enExample) |
| HR (1) | HRP20241316T1 (enExample) |
| HU (1) | HUE068840T2 (enExample) |
| IL (1) | IL262251B2 (enExample) |
| LT (1) | LT3443010T (enExample) |
| MA (1) | MA44665B1 (enExample) |
| MD (1) | MD3443010T2 (enExample) |
| MX (1) | MX2018012434A (enExample) |
| PH (1) | PH12018550160B1 (enExample) |
| PL (1) | PL3443010T3 (enExample) |
| RS (1) | RS66062B1 (enExample) |
| SA (1) | SA518400237B1 (enExample) |
| SI (1) | SI3443010T1 (enExample) |
| SM (1) | SMT202400438T1 (enExample) |
| UA (1) | UA126658C2 (enExample) |
| ZA (1) | ZA201806293B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3443010T3 (da) * | 2016-04-14 | 2024-09-30 | Ose Immunotherapeutics | Nye anti-SIRPa-antistoffer og terapeutiske anvendelser deraf |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| ES2963157T3 (es) * | 2017-07-26 | 2024-03-25 | Forty Seven Inc | Anticuerpos anti-SIRP-alfa y métodos relacionados |
| WO2019073080A1 (en) * | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF |
| CN112105646A (zh) | 2018-03-13 | 2020-12-18 | Ose免疫疗法 | 抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法 |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| WO2024053788A1 (ko) * | 2022-09-07 | 2024-03-14 | 주식회사 시프트바이오 | SIRPΑα 변이체에 특이적으로 결합하는 항체 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU1701001A (en) | 1999-11-30 | 2001-06-12 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibodies against signal regulator proteins |
| US20100215640A1 (en) | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| CN101970478A (zh) | 2007-10-11 | 2011-02-09 | 大学健康网络 | 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物 |
| BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2429574T3 (pl) | 2009-05-15 | 2015-12-31 | Univ Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie SIRP-CD47 |
| GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| CN109517897A (zh) | 2011-04-28 | 2019-03-26 | 南加利福尼亚大学 | 人类髓源抑制性细胞癌症标记 |
| WO2012172521A1 (en) * | 2011-06-16 | 2012-12-20 | Novartis Ag | Soluble proteins for use as therapeutics |
| US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| KR102276974B1 (ko) | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JP6606505B2 (ja) * | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 |
| CN105085679B (zh) * | 2014-04-25 | 2019-01-11 | 上海津曼特生物科技有限公司 | 全人源抗rankl抗体 |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| WO2016205042A1 (en) | 2015-06-16 | 2016-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα AGONIST ANTIBODY |
| EP4592391A3 (en) | 2015-10-21 | 2025-10-08 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| SG11201808465UA (en) | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| DK3443010T3 (da) | 2016-04-14 | 2024-09-30 | Ose Immunotherapeutics | Nye anti-SIRPa-antistoffer og terapeutiske anvendelser deraf |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| SG11201908813QA (en) * | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| US11274159B2 (en) | 2017-05-16 | 2022-03-15 | Byondis B.V. | Anti-SIRPα antibodies |
| ES2963157T3 (es) | 2017-07-26 | 2024-03-25 | Forty Seven Inc | Anticuerpos anti-SIRP-alfa y métodos relacionados |
| WO2019073080A1 (en) | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF |
| CN112105646A (zh) | 2018-03-13 | 2020-12-18 | Ose免疫疗法 | 抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法 |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| PE20210342A1 (es) | 2018-05-25 | 2021-02-23 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos |
| CN112673023B (zh) | 2018-07-10 | 2023-09-12 | 国立大学法人神户大学 | 抗SIRPα抗体 |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| WO2020102422A1 (en) | 2018-11-14 | 2020-05-22 | Arch Oncology, Inc. | THERAPEUTIC SIRPα ANTIBODIES |
| BR112021009275A2 (pt) | 2018-11-15 | 2022-01-04 | Byondis Bv | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. |
| WO2020180811A1 (en) | 2019-03-04 | 2020-09-10 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| AU2020286285A1 (en) | 2019-08-20 | 2021-03-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-SIRPa antibodies |
| CN111635458A (zh) | 2020-03-20 | 2020-09-08 | 上海健信生物医药科技有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
| CN112010979B (zh) | 2020-08-21 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人SIRPα单克隆抗体及其用途 |
| CN111995682B (zh) | 2020-08-21 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗人SIRPα单克隆抗体及其用途 |
| CN112574310B (zh) | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
-
2017
- 2017-04-14 DK DK17718881.0T patent/DK3443010T3/da active
- 2017-04-14 SI SI201731557T patent/SI3443010T1/sl unknown
- 2017-04-14 US US16/093,062 patent/US11279766B2/en active Active
- 2017-04-14 SM SM20240438T patent/SMT202400438T1/it unknown
- 2017-04-14 JP JP2018550322A patent/JP7491666B2/ja active Active
- 2017-04-14 FI FIEP17718881.0T patent/FI3443010T3/fi active
- 2017-04-14 MX MX2018012434A patent/MX2018012434A/es unknown
- 2017-04-14 RS RS20241172A patent/RS66062B1/sr unknown
- 2017-04-14 EP EP24190165.1A patent/EP4438626A3/en active Pending
- 2017-04-14 MD MDE20190221T patent/MD3443010T2/ro unknown
- 2017-04-14 ES ES17718881T patent/ES2990971T3/es active Active
- 2017-04-14 KR KR1020187032968A patent/KR102355240B1/ko active Active
- 2017-04-14 CN CN202310060526.8A patent/CN115785272A/zh active Pending
- 2017-04-14 HR HRP20241316TT patent/HRP20241316T1/hr unknown
- 2017-04-14 LT LTEPPCT/EP2017/059071T patent/LT3443010T/lt unknown
- 2017-04-14 UA UAA201809487A patent/UA126658C2/uk unknown
- 2017-04-14 IL IL262251A patent/IL262251B2/en unknown
- 2017-04-14 HU HUE17718881A patent/HUE068840T2/hu unknown
- 2017-04-14 MA MA44665A patent/MA44665B1/fr unknown
- 2017-04-14 PH PH1/2018/550160A patent/PH12018550160B1/en unknown
- 2017-04-14 PL PL17718881.0T patent/PL3443010T3/pl unknown
-
2018
- 2018-09-19 ZA ZA2018/06293A patent/ZA201806293B/en unknown
- 2018-10-11 CL CL2018002898A patent/CL2018002898A1/es unknown
- 2018-10-14 SA SA518400237A patent/SA518400237B1/ar unknown
-
2022
- 2022-02-25 US US17/681,219 patent/US12252546B2/en active Active
- 2022-07-14 JP JP2022112873A patent/JP7549626B2/ja active Active
-
2025
- 2025-03-11 US US19/076,531 patent/US20250215108A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520034A5 (enExample) | ||
| JP2022169504A5 (enExample) | ||
| TWI701259B (zh) | ４﹘１ｂｂ抗體及其製備方法和應用 | |
| CN109843927B (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| US9273136B2 (en) | Fully human anti-human NKG2D monoclonal antibodies | |
| CN113543804A (zh) | 抗lilrb2抗体及其使用方法 | |
| BR112021010394A2 (pt) | Anticorpo anti-4-1bb e uso do mesmo | |
| JP2020504095A (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP2020504171A (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| CN110267989B (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| JP2018531914A (ja) | ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法 | |
| CN116693686A (zh) | 抗b7-h4抗体、其抗原结合片段及其医药用途 | |
| KR20160024391A (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| KR20200079561A (ko) | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 | |
| CN107266571A (zh) | 抗‑mcam抗体及相关使用方法 | |
| SG187945A1 (en) | Anti-ox40 antibodies and methods of using the same | |
| KR20100014588A (ko) | 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 | |
| JP2021500916A5 (enExample) | ||
| CN112969714A (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| CN115785272A (zh) | 新型抗-SIRPa抗体及其治疗应用 | |
| CN114591434B (zh) | 抗Siglec15抗体及其制备方法和用途 | |
| US20210379194A1 (en) | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications | |
| WO2022143552A1 (zh) | Pd-1结合分子及其应用 | |
| CA3121420A1 (en) | Anti-il-27 antibodies and uses thereof | |
| US20150125397A1 (en) | Dual specific binding proteins directed against immune cell receptors and autoantigens |